EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    1.4.3.21 | Acute Kidney Injury |
28318627 |
Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 1.4.3.21 | Acute Kidney Injury |
30633060 |
Vascular Adhesion Protein-1 Is Associated With Acute Kidney Injury in High-Risk Patients After Cardiac Surgery. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
4
2 |
| 1.4.3.21 | Acute Kidney Injury |
31512003 |
Association of endothelial and glycocalyx injury biomarkers with fluid administration, development of acute kidney injury, and 90-day mortality: data from the FINNAKI observational study. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
2
3
0 |
| 1.4.3.21 | Acute Kidney Injury |
31743166 |
Vascular Adhesion Protein-1 Is Associated With Acute Kidney Injury in High-Risk Patients After Cardiac Surgery. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
4
3 |
| 1.4.3.21 | Acute Lung Injury |
18991279 |
Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
4
4
0 |
| 1.4.3.21 | Adenocarcinoma |
20523988 |
PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG. |
ongoing research
unassigned |
3
0 |
| 1.4.3.21 | Albuminuria |
30413396 |
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. |
ongoing research
therapeutic application
unassigned |
4
4
0 |
| 1.4.3.21 | Albuminuria |
32929612 |
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
3
0 |
| 1.4.3.21 | Albuminuria |
32930923 |
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
3
4
0 |
| 1.4.3.21 | Alzheimer Disease |
21405023 |
Novel Hydrazine Molecules as Tools To Understand the Flexibility of Vascular Adhesion Protein-1 Ligand-Binding Site: Toward More Selective Inhibitors. |
causal interaction
unassigned |
4
0 |
